Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teplizumab Safety in Recent-Onset Type 1 Diabetes Relatives
NCT04270942Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2020
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teplizumab in type 1 diabetes mellitus (T1D), sponsored by Sanofi. Primary endpoint: Number of Participants With Treatment-emergent Adverse Events at 78 weeks. Started Feb 2020; status: completed.
02
Drugs
teplizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04270942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04270942.